At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
STSP-0601 for Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Open-label, Phase Ⅱb Trial to Evaluate the Safety and Efficacy of STSP-0601 for Injection in Patients with Hemophilia with Inhibitor
Staidson (Beijing) Biopharmaceuticals Co., Ltd·interventional·Posted Mar 1, 2024·Updated Jan 22, 2025
In Brief
A Phase 2 clinical trial evaluating STSP-0601 for Injection for Hemophilia. Completed, enrolled 25 participants across 20 sites.
Detailed Summary
This study will assess the safety and efficacy of multiple-dose of STSP-0601 for the treatment of bleeding episodes in hemophilia A or B patients with inhibitor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemophilia
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20252026
First PostedMar 2024
Enrollment StartMar 2024
Primary CompletionOct 2024
TodayJul 2026
First PostedMar 1, 2024
Enrollment StartMar 18, 2024
Primary CompletionOct 17, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 2.3 years ago
Interventions
STSP-0601 for Injectiondrug
A Multiple-dose Design to Evaluate the Safety, Tolerability and Efficacy of STSP-0601 for Injection in hemophilia A or B patients with inhibitor.